AAA Fully Acquires Atreus Pharmaceuticals; Enrolls First Patient in a Phase I/II Clinical Trial for Its Key Diagnostic Candidate Annexin v-128 in Rheumatoid Arthritis
Advanced Accelerator Applications S.A. ("AAA" or "the Company"), an international specialist in Molecular Nuclear Medicine (MNM), announced that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.
View full press release